Trial Profile
Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Mar 2018
Price :
$35
*
At a glance
- Drugs Maveropepimut-S (Primary) ; Cyclophosphamides
- Indications Glioblastoma
- Focus Biomarker; Pharmacodynamics
- 26 Mar 2018 New trial record